Author
1. Chawla Rajeev
2. Jaggi Shalini
ISBN
9789352706808
DOI
10.5005/jp/books/18340_8
Edition
1/e
Publishing Year
2020
Pages
9
Author Affiliations
1.
North Delhi Diabetes Center, New Delhi, India,
North Delhi Diabetes Centre, Delhi, India,
North Delhi Diabetes Centre, New Delhi, India,
RSSDI,
North Delhi Diabetes Centre, Rohini, New Delhi, India,
Maharaja Agrasen Hospital, Punjabi Bagh, New Delhi; Rohini, New Delhi, India,
North Delhi Diabetes Centre, New Delhi
2.
Dr Mohans’ Diabetes Specialities Centre, New Delhi, India,
Dr Mohan Diabetes Specialities Centre, New Delhi, India,
Lifecare Diabetes Centre, Kirti Nagar, New Delhi, India,
Lifecare Diabetes Centre, New Delhi, India,
Dr Mohans’ Diabetes Specialities, Center, New Delhi, India,
Dr Mohans’ Diabetes Specialities Center, New Delhi, India,
Dr Mohans’ Diabetes Specialities Center, New Delhi, India,
Dr Mohans' Diabetes Specialties Centre, New Delhi, India,
Dr Mohan’s Diabetes Specialities Centre, New Delhi, India,
Dr Mohans' Diabetes Specialities Center, New Delhi, India,
Dr Mohan’s Diabetes Specialities Center, New Delhi, India,
Dr Mohans' Diabetes Specialities Centre, New Delhi, India
Chapter keywords
SGLT-2 inhibitor,
diabetes,
β-cell function,
atherosclerotic cardiovascular disease,
ASCVD,
type 2 diabetes mellitus,
T2DM,
pharmacotherapy,
glucagon-like peptide-1,
heart failure,
chronic kidney disease,
CKD,
hypertension,
estimated glomerular filtration rate,
eGFR
